Activated microglia, involved in the occurrence and improvement of sepsis-associated encephalopathy, can induce the expression of pro-inflammatory cytokines and pro-inflammatory enzymes, resulting in inflammation-mediated neuronal cell death. It was reported that propofol could inhibit lipopolysaccharide (LPS)-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression in BV2 and primary microglial cells. However, the underlying mechanism is not well known.
In the present study, we investigated whether and how propofol inhibited LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in BV2 cells. LPS induced pro-inflammatory cytokines and pro-inflammatory enzymes expression, NF-κB, by a systemic inflammation without a direct brain infection in critically ill patients (Girard et al. 2010; Gofton and Young 2012; Iwashyna et al. 2012) , and it is a common syndrome, which is associated with an increased rate of morbidity and mortality in sepsis patients. It is reported that microglia activation is involved in the occurrence and progression of sepsis-associated encephalopathy (Michels et al. 2015) . Activated microglia can induce the expression of pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6) (Michels et al. 2015) , and pro-inflammatory enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase II (COX II) (Fu et al. 2014) , resulting in inflammation-mediated neuronal cell death.
Studies have indicated that extracellular regulated kinase 1/2 (ERK1/2) and NF-κB activation plays an important role in pro-inflammatory enzymes and cytokines expression in LPS-treated BV2 cells (a microglia cell line) Matsuda et al. 2003; Sakon et al. 2003) .
The intravenous general anesthetic propofol is frequently employed for the sedation of critically ill patients. Previous studies indicated that propofol could inhibited lipopolysaccharide (LPS)-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in BV2
and primary microglial cells (Luo et al. 2013; Peng et al. 2014) . However, D r a f t the underlying mechanisms by which propofol inhibited LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression have not been well studied. In the present study, we investigated whether and how propofol inhibited LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes in BV2 cells.
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MATERIALS AND METHODS
Cell culture and reagent
BV2 cells were cultured in DMEM and 10% fetal bovine serum in incubator containing 5% CO 2 at 37 °C. Cells were sub-cultured when reaching 90% confluence.
KN93 (an inhibitor of CaMK II), MK801 (an inhibitor of NMDA receptor) and rapastinel (an activator of NMDA receptor), were purchased form Sigma (St. Louis, MO)
Study design
Cells were cultured with 1µg/ml LPS for 6h. At the end of 4h incubation, cells were co-incubated with different concentrations (5, 25, 50 and 100µM) of propofol for the last 2h. The optimal concentration of propofol with significant inhibitory effects on pro-inflammatory cytokines and pro-inflammatory enzymes expression was determined.
These treatment conditions were used in the following studies in which cells were cultured and divided into six groups to examine the underlying signaling pathways. Group 1: cells were cultured in DMEM as control;
Group 2: cells were treated with 1µg/ml LPS for 6h; Group 3: cells were treated with LPS for 4h, followed by co-incubation with 50µM propofol for the last 2h; Group 4: cells were treated with LPS for 4h, followed by D r a f t co-incubation with 10µM KN93 for the last 2h; Group 5: cells were treated with LPS for 4h, followed by co-incubation with 25µM MK801
for the last 2h; Group 6: cells were treated with LPS for 4h, followed by co-incubation with 50µM propofol and 10µM rapastinel for the last 2h.
Real-time quantitative RT-PCR
Total RNA extracts were prepared with the use of trizol (Invitrogen). 
RESULTS
Propofol inhibits LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression.
In BV2 
LPS-mediated ERK1/2 and NF-κB phosphorylation, and its
Modulation by propofol, KN93, MK801 and rapastinel.
KN93 and MK801 inhibited LPS-induced ERK1/2 and NF-κB phosphorylation ( Figure 5A -C, p<0.05 compared with LPS treatment), which was similar with propofol. Moreover, the effects of propofol could be counteracted by rapastinel ( Figure 5A -C).
LPS-mediated pro-inflammatory cytokines and pro-inflammatory enzymes expression, and its modulation by Propofol, KN93, MK801 and rapastinel.
KN93 and MK801 inhibited LPS-mediated the expression of pro-inflammatory cytokines and pro-inflammatory enzymes (Figure 6, p<0 .05 compared with LPS treatment), which was similar with propofol.
Moreover, the effects of propofol could be inhibited by rapastinel ( Figure   6 ).
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DISCUSSION
In the present study, we found that propofol could inhibit LPS-induced BV2 cells inflammation via attenuating LPS-mediated expression of pro-inflammatory cytokines and pro-inflammatory enzymes.
Our data also suggested that the protective effects of propofol might be achieved by inhibiting NMDA receptor, inhibiting LPS-mediated Ca Shibuta et al. 2001; Trapani et al. 2000) . In the present study NMDA receptor was also found to be expressed in the BV2 cells ( Figure 4A ). NMDA R2B has been found to exhibit a main channel function in brain (Carroll and Zukin 2002; Sobczyk et al. 2005 ).
Activation of NMDA receptors containing GluN2B subunit causes Ca Propofol was reported to inhibit NMDA subtype of glutamate receptor via an allosteric modulation of channel gating, thus decreased the probability of cannel opening (Orser et al. 1995) . In the present study, the expression of NMDA R2B was not affect by propofol, however we found propofol inhibited LPS-induced Ca 2+ accumulation and CaMK II phosphorylation, thus attenuating LPS-mediated BV2 cells activation. Our study also indicated that the protective effect of propofol is similar with MK801, an inhibitor of NMDA receptor. Moreover, the protective effects of propofol could be reversed by rapastinel, an activator of NMDA receptor. These result strongly indicated that the protective effects of propofol on LPS-mediated BV2 cells inflammation was achieved by inhibition of NMDA receptor.
In the present study, 50uM Propofol was found to attenuate LPS-induced BV2 cells inflammation. In patients, the brain concentrations of propofol during anesthesia ranged from 11 to 33µM (Ellerkmann et al. 2004; Iannuzzi et al. 2005; Kreuer et al. 2004) , and high concentrations of propofol could be more damaging than beneficial.
However, it was reported that in murine the concentration of propofol in whole brain during anesthesia is about 75µM (Shyr et al. 1995) . In the present study, we used BV2, which is a murine microglia cell line.
Therefore, in this study, 50µM propofol was considered to be an D r a f t appreciate concentration of propofol to study the protective effect of propofol against LPS-induced inflammation in BV2 cells. However, the present study needs to be further confirmed by in vivo study.
The present study has some limitations. First, the study was carried out in BV2 cells, which is an in vitro system. It differs from in vivo settings, especially considering effectiveness and toxicity of medicine.
Second, BV2-HT22 neuronal co-culture was not used to evaluate the effects of propofol on inflammation-induced neuronal death. Further studies using BV2-HT22 neuronal co-culture are necessary to clarify these issues.
In summary, the present study suggested that LPS, by inducing Ca . LPS-mediated CaMK II phosphorylation and Ca2+ accumulation, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus repastinel for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to NMDA R2B, CaMK II and p-CaMK II. (B) The protein expression ratio of NMDA R2B and β-actin. The ratio in the control group was set as 1. (C) The protein expression ratio of p-CaMK II and CaMK II. The ratio in the control group was set as 1. (D) propofol inhibited LPS-mediated Ca2+ accumulation, which was similar to MK801. Moreover, the effect of propofol could be counteracted by rapastinel. KN93 had no effect on cells Ca2+ concentration. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, ＆P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.) 209x250mm (300 x 300 DPI) D r a f t Figure 5 . LPS-mediated ERK1/2 and NF-κB phosphorylation, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus repastinel for the last 2h. (A) Equal amounts of proteins were separated by SDS-PAGE and immunoblotted with antibodies to p-NF-κB, p-ERK1/2 and ERK1/2. (B) The protein expression ratio of p-NF-κB and β-actin. The ratio in the control group was set as 1. (C) The protein expression ratio of p-ERK1/2 and ERK1/2. The ratio in the control group was set as 1. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, ＆P < 0.05 vs. propofol treatment, n = 5. Data are shown as mean ± SD.) 209x250mm (300 x 300 DPI) D r a f t Figure 6 . LPS-induced pro-inflammatory cytokines and pro-inflammatory enzymes expression, and its modulation by propofol, KN93, MK801 and rapastinel. BV2 cells were treated with 1µg/ml LPS for 4h, followed by co-incubation with propofol, KN93, MK801 or propofol plus repastinel for the last 2h. (A-F) Propofol inhibited LPS-induced the expression of pro-inflammatory cytokines and pro-inflammatory enzymes, which was similar to KN93 and MK801. Moreover, the effect of propofol could be counteracted by rapastinel. (*P < 0.05 vs. control, #P < 0.05 vs. LPS treatment, ＆P < 0.05 vs. propofol treatment, n = 5.
Data are shown as mean ± SD.) 209x250mm (300 x 300 DPI)
